A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer

Pengfei Jiang; Lude Wang; Bailong Hou; Jinshun Zhu; Meng Zhou; Jie Jiang; Ledan Wang; Shao Chen; Shanli Zhu; Jun Chen; Lifang Zhang

doi:10.7150/thno.24607

. 2018 Jun 7;8(13):3544–3558. doi: 10.7150/thno.24607

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer

Pengfei Jiang ^1,^*, Lude Wang ^1,^*, Bailong Hou ^1,^*, Jinshun Zhu ¹, Meng Zhou ¹, Jie Jiang ¹, Ledan Wang ², Shao Chen ¹, Shanli Zhu ¹, Jun Chen ¹, Lifang Zhang ^1,^✉

PMCID: PMC6037027 PMID: 30026865

Abstract

Cervical cancer, the second most common cause of cancer death in women worldwide, is significantly associated with infection of high-risk human papillomaviruses (HPVs), especially the most common genotype, HPV 16. To date, there is no established noninvasive therapy to treat cervical cancer.

Methods: Here, we report a novel affitoxin that targets HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, Z_HPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. The expressed and purified Z_HPV16E7 affitoxin384 was characterized using numerous methods. SPR assay, indirect immunofluorescence assay, and near-infrared (NIR) optical imaging were respectively performed to assess the targeting ability of Z_HPV16E7 affitoxin384 to HPV16 E7 protein both in vitro and in vivo. Cell viability assays and SiHa tumor-bearing nude mice were used to evaluate the efficacy of Z_{HPV16 E7} affitoxin384 in vitro and in vivo, respectively.

Results: Using in vitro methods the SPR assay and indirect immunofluorescence assay showed that Z_HPV16E7 affitoxin384 targeted HPV16 E7 with high binding affinity and specificity. Significant reduction of cell viability in HPV16 positive cells was observed in the presence of Z_{HPV16 E7} affitoxin384. By NIR optical imaging, Z_{HPV16 E7} affitoxin384 specifically targeted HPV16 positive tumors in vivo. Z_HPV16E7 affitoxin384 showed significant in vivo antitumor efficacy in two kinds of tumor-bearing nude mouse models.

Conclusions: Z_HPV16E7 affitoxin384 is a potent anti-cervical cancer therapeutic agent that could be effective against HPV16 positive tumors in humans.

Keywords: HPV16, affitoxin, targeted therapy, cervical cancer

Introduction

Cervical cancer is the second most common cause of cancer-related death in women worldwide, especially in developing countries. Approximately 445,000 new cases of cervical cancer are diagnosed each year and 270,000 deaths ¹. Evidence from clinical, epidemiological, and molecular data studies has demonstrated that infections of high-risk types of human papillomaviruses (HPVs) such as HPV16, 18, 31, 33, 35, 45, 52, and 58 are significantly associated with cervical cancer development. Among these high-risk types, HPV16 is the most common worldwide HPV genotype, which is responsible for approximately 50% of cervical cancer cases ²^,³. Although the commercial HPV vaccines are highly efficient in preventing HPV infection, there is no established noninvasive therapy to treat the HPV-associated lesions such as squamous intraepithelial lesions and cervical cancer. Therefore, the development of effective treatment strategies needs urgent attention.

HPV is a non-enveloped, double-stranded, circular DNA virus. Its genome is composed of about 8000 base pairs, which encodes six to seven early proteins (E1, E2, E4, E5, E6, E7 and E8), and two late structural proteins (L1 and L2). HPV infection can lead to the transformation of basal epithelial cells. In the process of the transformation, up-regulated E6 and E7 oncoproteins principally contribute to malignant transformation and retain the malignant phenotype of cervical cancers ⁴^-⁶. Therefore, HPV E6 and E7 proteins may be excellent target proteins in molecular targeted therapy for HPV-induced cervical cancer ⁷^-¹⁰.

To date, monoclonal antibodies (mAbs) are the most successful proteins applied in molecular targeted therapy ¹¹^-¹³. However, mAbs still have some disadvantages (reviewed by Patrick, et al.) ¹⁴. Firstly, it is difficult to produce the active form of mAbs because of their large molecular weight (about 150 kD) and multiple posttranslational modifications such as glycosylation. Secondly, only a small percentage of the administered dose of mAbs can target tumors because most mAbs bind to tumor-specific antigens in the blood. Thirdly, it is difficult for mAbs to reach their target cells in solid tumors because of their poor tissue-penetrating ability. Affibodies, derived from the Z-domain of Staphylococcal protein A (SPA-Z) and based on a 58 amino-acid scaffold, are a new class of affinity proteins with high affinity and specificity ¹⁵^-¹⁹. Affibodies have the favorable molecular recognition properties of antibodies with improved characteristics, such as small size (~7 kDa) (affibodies are almost 20 times smaller than full-size antibodies and four times smaller than single-chain variable fragment (scFvs)), single domain, high stability, absence of cysteines, fastest folding reaction, high yield bacterial expression and low immunogenicity ²⁰. Therefore, affibodies and their derivatives are attractive surrogates for antibodies or scFvs in tumor targeted therapy ²¹^-²³.

In our previous study, we generated four HPV16 E7-specific affibodies (Z_HPV16E7127, Z_HPV16E7301, Z_HPV16E7384, and Z_HPV16E7745) using phage display technology ²⁴. In order to enhance the cytotoxic efficacy, we connected the modified Pseudomonas Exotoxin A (PE38KDEL) toxin ²⁵ to the N terminal of Z_HPV16E7384 by a flexible peptide (Gly4Ser)3 to generate HPV16 E7-specific affibody-PE38KDEL toxin molecule (named as Z_{HPV16 E7} affitoxin384). In this study, we report the characterization of this novel recombinant protein Z_{HPV16 E7} affitoxin384 for its binding ability to recombinant and native HPV16 E7 protein, its cytotoxic effect on HPV16 positive cervical cancer cell lines, and the in vivo evaluation of targeted therapy for cervical cancer in tumor-bearing nude mice.

Methods

Animals, cells and vectors

Female athymic nude mice (nu/nu genotype, BALB/c background) and BALB/c mice, 6 to 8 weeks old, were purchased from Shanghai SLAC Laboratory Animal Co. Ltd and kept at the animal facility of Wenzhou Medical University, China. ICR mice, weighing 23-27 g, were purchased from the animal experimental center of Wenzhou Medical University, China. All of the animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. SiHa (ATCC: HTB-35, HPV16 positive, contains about one to two copies of integrated HPV16 genome), CaSki (ATCC: CRL-1550, HPV16 positive, contains about 600 copies of integrated HPV16 genome), HeLa 229 (ATCC: CCL-2.1, HPV18 positive, used as HPV16 negative control cell line), and melanoma tumor A375 (ATCC: CRL-1619, used as HPV negative control cell line) were obtained from the American Type Culture Collection (ATCC, USA) and cultured as previously described ²⁴. The pET21a(+) vector and E.coli BL21 (DE3) were purchased from Novagen and ATCC, respectively.

Reagents

The reagents used, including Cell Counting Kit-8 (CCK-8) (Dojindo, Japan), RPMI-1640 (Gibco, USA), fetal bovine serum (FBS) (Gibco, USA), penicillin (Gibco, USA), trypsin-EDTA (Gibco, USA), streptomycin (Sigma Aldrich, Saint Louis, USA), Isopropyl-D-thiogalactopyranoside (IPTG) (Sigma Aldrich, Saint Louis, USA), Ni-NTA agarose (Qiagen Inc., Valencia, CA), and DyLight-755 (Thermo Fisher Scientific, USA), were purchased from commercial sources. The anti-HPV16 E7 rabbit polyclonal antibody and anti-His tag mouse monoclonal antibody (Abcam, Boston, MA, USA), goat anti-rabbit IgG (H+L) conjugated with HRP and goat anti-mouse IgG (H+L) conjugated with HRP, goat anti-rabbit antibody conjugated with FITC and goat anti-mouse antibody conjugated with alexa fluor 647 (MultiSciences Biotech Co., Ltd, China) were purchased from commercial sources. The mouse immune serum anti-PE38KDEL, rabbit immune serum anti-SPA-Z and anti-HPV16 E7 recombinant proteins were prepared in our laboratory ²⁶^,²⁷.

Expression and purification of Z_HPV16E7 affitoxin384

A random combinatorial phage display library with 1×10⁸ variants of protein SPA-Z had been prepared by using phage display technology in our laboratory, from which four affibodies specifically binding to HPV16 E7 were selected ²⁴. The Z_HPV16E7384 was selected to construct an affitoxin for further study.

The toxin part used in this study was the mutant fragment of Pseudomonas Exotoxin A with the C-terminal part optimized to KDEL sorting signal and then the toxin was named as PE38KDEL ²⁸^,²⁹. PE38KDEL was ligated to the C-terminus of Z_HPV16E7384 polypeptide by a flexible (Gly4Ser)3-linker domain. In brief, the DNA sequence corresponding to PE38KDEL with (Gly4Ser)3-linker domain modified based on prokaryotic codon usage by the JCat software (Java Codon Adaptation Tool, http://www.jcat.de/) was synthesized by Shanghai Sangon Biotech Co. Ltd and then cloned into vector pET21a (+) between the EcoR I and Xho I sites to generate the recombinant plasmid pET21a (+)/PE38KDEL. The DNA sequence of Z_HPV16E7384 was amplified by PCR using the plasmid pet21a (+)/Z_{HPV16 E7}384 as a template ²⁴ and cloned into the pET21a (+)/PE38KDEL vector in frame with the 6×His tag between Nde I and EcoR I sites to generate the recombinant plasmid pET21a (+)/Z_HPV16E7 affitoxin384 (The protein encoded by this vector was named as Z_HPV16E7 affitoxin384). Meanwhile, SPA-Z molecule (Z_wt), was used as a negative control. The plasmid pET21a (+)/Z_wt affitoxin (Z_wt affitoxin) was constructed in the same method as Z_{HPV16 E7} affitoxin384. The two recombinant plasmids were confirmed by sequencing.

The expression of Z_{HPV16 E7} affitoxin384 and Z_wt affitoxin in E. coli BL21 (DE3) was induced by 1 mM IPTG (Sigma-Aldrich Co., St. Louis, MO) and verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis. Then, the proteins were purified by Ni NTA Sepharose column (Qiagen Inc., Valencia, CA) as described in previous study ²⁴.

Western blot analysis

Western blot analysis was performed to confirm the expression of Z_{HPV16 E7} affitoxin384 and Z_wt affitoxin. Whole cell lysates were run on a 12% SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride membranes (Millipore, USA). Membranes were blocked with 10% skim milk in PBST (1× PBS + 0.1% Tween-20) for 2 h, incubated with indicated primary antibodies, and then incubated with HRP-conjugated secondary antibody. The protein bands were visualized using 0.005% (w/v) 4-chloro-1-naphthol and a 0.015% (v/v) hydrogen peroxidase color development substrate.

Surface plasmon resonance assay

To assess the interaction between the HPV16 E7 protein and Z_{HPV16 E7} affitoxin384, surface plasmon resonance (SPR) assay was performed with the ProteOn XPR36 protein interaction array system (Bio-Rad Laboratories, USA) as described in a previous study ²⁴. Z_wt affitoxin was used as a negative control. The processed data was fit globally using BIA evaluation software (version 3.0.2; Biacore) for a 1:1 Langmuir model.

Indirect immunofluorescence assay

To assess the in vitro targeting ability of Z_{HPV16 E7} affitoxin384, indirect immunofluorescence assay was performed as described in a previous study ²⁴. In brief, SiHa, CaSki, HeLa and A375 cells were seeded in dishes suitable for confocal microscopy observation. After incubation for 24 h, the medium was replaced with fresh challenge media supplemented with 50 μM of Z_{HPV16 E7} affitoxin384, Z_{HPV16 E7}384 or Z_wt affitoxin. Cells were analyzed after treatment for 6 h. The cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. Then, cells were washed with cold 0.01 M PBST, and placed in blocking buffer (PBS containing 5% FBS) at 4 °C overnight, followed by incubation with indicated primary antibodies for 1 h at room temperature. The cells were washed with cold PBST three times and incubated with indicated secondary antibodies for 1 h at room temperature. Cell nuclei were stained with 50 μg/mL propidium iodide (PI) (MultiSciences Biotech Co., Ltd China) at room temperature for 5 min. The cells were analyzed by a confocal fluorescence microscope (TC-1, Nikon, Japan).

To further confirm the specific binding ability of Z_{HPV16 E7} affitoxin384 to HPV16E7 protein, the co-localization was determined in SiHa cells expressing HPV16 E7 protein by confocal double immunofluorescence assay. The experimental procedure was similar to the description mentioned above.

In vitro efficacy of Z_{HPV16 E7} affitoxin384

To evaluate the efficacy of Z_{HPV16 E7} affitoxin384, cell viability assay was performed with CCK-8 kit (Dojindo) as described in a previous study with minor modifications ³⁰. Briefly, SiHa, CaSki, HeLa and A375 cells were plated onto a 96-well plate at 1×10⁴ cells per well, followed by treatment with Z_{HPV16 E7} affitoxin384 at different concentrations (0.1, 0.25, 0.5, 1.0 and 2.0 μM). Cells treated with the same concentrations of Z_wt affitoxin were used as negative controls. Cell viability was determined after incubation for 0, 1, 3, 6, 12, 24, 36, 48 and 72 h, respectively. According to the manufacturer's instructions, 10 µL of CCK-8 solution was added to each well of the 96-well plate and then incubated for an additional 4 h. Absorbance was measured at 450 nm using a microplate reader (Synergy HT; BioTek, Winooski, VT, USA). The percentage of cell viability was calculated according to the following formula: Cell viability (%) = optical density (OD) of the treatment group/OD of the control group × 100%. The half maximal inhibitory concentration (IC₅₀) values were calculated using GraphPad Prism software (GraphPad Software, Inc.).

Tumor targeting ability of Z_{HPV16 E7} affitoxin384 in tumor-bearing nude mice

The dynamic distribution and tumor targeting ability of Z_{HPV16 E7} affitoxin384 were investigated in nude mice using near-infrared (NIR) optical imaging. Briefly, 1×10⁷ of SiHa, CaSki, Hela and A375 cells were respectively injected subcutaneously into the right forelimb of nude mice (n = 5 per group). When the tumor size reached 0.3-0.4 cm in diameter, mice were used for NIR imaging and treatment. Z_{HPV16 E7} affitoxin384, Z_{HPV16 E7}384 (the positive control) and Z_wt affitoxin (the negative control) were labeled with a maleimide derivative of DyLight-755 (Thermo Fisher Scientific, USA, 62278) by attaching the dye to the native lysine residues of affibody molecules according to the manufacturer's protocol. Then, 200 pmol of affibody-DyLight-755 or affitoxin-DyLight-755 dissolved in 100 μL of PBS were injected intravenously. The fluorescence imaging was performed at various time points post-injection using an NIR imaging system (CRi Maestro 2.10, USA). The tumor/muscle ratios (T/M ratio) (T/M ratio = (tumor signal - background signal) / (muscle signal - background signal) × 100%) were analyzed at various time points post injection. The mice were sacrificed at 48 h after the imaging study, and the tumor and dissected organs such as liver, spleen, brain and other organs were analyzed using NIR optical imaging fluorescence analysis.

Evaluation of Z_{HPV16 E7} affitoxin384 acute toxicity

BALB/c female mice (n = 5 per group) were administered with the indicated doses (5, 10, 20, 50, 100, 200, 300, 400 and 500 nmol/kg) of Z_{HPV16 E7} affitoxin384 by intravenous injection into the tail vein. Any reported death cases or moribund conditions that occurred within the 2-week post injection period were taken into consideration. All experiments were performed in triplicate. The lethal dose 50% (LD50) value was calculated by GraphPad Prism 5.0 Software.

A total of 96 ICR mice were randomly divided into 4 groups. Mice in group 2, 3, and 4 were respectively administered the indicated doses (20, 100, and 200 nmol/kg) of Z_{HPV16 E7} affitoxin384 by intravenous injection into the tail vein, while mice from group 1 were administered PBS as a control. Blood samples were collected at day post-injection (DPI) 1, 3, 7, and 14 in EDTA tubes for complete blood count and in plain tubes for liver and kidney function panel test (n=3 mice per time point per test). Then, blood samples in EDTA tubes were analyzed using a Mindray BC-5380 Hematology Analyzer (Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, China) and serums generated from blood samples in plain tubes were analyzed using a Beckman AU680 Chemistry Analyzer (Beckman Coulter, Brea, CA, USA).

Pharmacokinetics of Z_{HPV16 E7} affitoxin384

Nude mice were divided into 2 groups (n = 3 per group) for intravenous administration of Z_{HPV16 E7} affitoxin384 (100 nmol/kg) or PBS, respectively. A total of 100 μL of blood was respectively collected at 1, 5, 15, 30, 60 and 120 min post injection from each mouse. At 5 h post injection (hpi), the mice were anesthetized and terminally bled. Blood samples were obtained from the fossa orbitalis and serum levels of Z_{HPV16 E7} affitoxin384 were measured by recombinant HPV16E7 protein-based ELISA. Briefly, a 96-well plate was coated with purified HPV16E7 protein (100 μg/mL) in carbonate coating buffer (100 μL/well). After an overnight incubation at 4 °C, the plates were rinsed with PBS solution containing 0.05% Tween-20. The coated wells were blocked with 100 μL blocking buffer (PBST containing 5% nonfat dry milk, w/v) at 37 °C for 1 h then washed five times with PBST. Blood samples (at a dilution of 1:100 and 100 μL/well) were added to the wells in triplicate, followed by incubation at 37 °C for 2 h. The rabbit anti-SPA-Z serum polyclonal antibody (at a dilution of 1:2000 and 100 μL/well) and the HRP-conjugated goat anti-rabbit IgG (H1L) (ABR, USA) (at a dilution of 1:5000 and 100 μL/well) were added to the corresponding wells and incubated for 1 h at 37 °C. The wells were washed again, followed by the addition of 100 μL/well of 3, 39, 5, 59-tetramethylbenzidine-H₂O₂ solution. The reaction was carried out at room temperature for 20 min and halted with 50 μL of 2 M of H₂SO₄ per well. The absorbance at 450 nm was measured using a Bio-tek ELISA microplate reader. Meanwhile, a second 96-well plate was coated with purified HPV16E7 protein, followed by adding the rabbit serum anti-HPV16E7 or anti-SPA-Z instead of adding the blood sample as positive and negative controls, respectively. To make a standard concentration curve, a 96-well plate was respectively coated with the Z_{HPV16 E7} affitoxin384 protein at various concentrations (0, 0.002, 0.02, 0.2 and 2 nM) and detected by ELISA as described above. The circulation half-lives and initial concentrations of the proteins were calculated using GraphPad Prism 5.0 Software.

In vivo antitumor efficacy of Z_{HPV16 E7} affitoxin384

Therapeutic efficacy of Z_{HPV16 E7} affitoxin384 was studied using SiHa tumor-bearing nude mice by two methods. The first method was that SiHa tumor-bearing mice were prepared in advance, followed by injection of Z_{HPV16 E7} affitoxin384. Briefly, nude mice were randomly divided into 5 groups (n= 5 per group). The tumors were initiated by subcutaneous injection of 1×10⁷ cells, which were suspended in 0.1 mL of PBS, into the right forelimb of each nude mouse. Tumor dimensions were measured periodically using calipers, and their volumes calculated using the formula: volume = length × width² × 0.52. When the tumor size reached 0.1-0.2 cm in diameter, mice were treated with 0.2 mL of Z_{HPV16 E7} affitoxin384 (100 nmol/kg), Z_wt affitoxin (100 nmol/kg), Z_{HPV16 E7}384 (100 nmol/kg), PE38KDEL (100 nmol/kg), or PBS, respectively. The indicated agents were injected every three days for six time points via tail vein. The therapeutic efficacies and systemic toxicities of affitoxin proteins were evaluated based on daily measurements of tumor volume and body weight. Tumors from mice in the aforementioned five groups were separated and weighed after all treatments and observations were finished.

The second method involved simultaneous injection of Z_{HPV16 E7} affitoxin384 and preparation of SiHa tumor-bearing mice. Briefly, nude mice were randomly divided into 5 groups (n= 5 per group). The tumors were initiated by subcutaneous injection of 1×10⁷ cells, which were suspended in 0.1 mL of PBS, into the right forelimb of each nude mouse. Meanwhile, mice were treated with 0.2 mL of Z_{HPV16 E7} affitoxin384 (100 nmol/kg), Z_wt affitoxin (100 nmol/kg), Z_{HPV16 E7}384 (100 nmol/kg), PE38KDEL (100 nmol/kg), and PBS, respectively. The indicated agents were injected every three days for six time points via tail vein. Tumor dimensions were measured as mentioned above. The therapeutic efficacies and systemic toxicities of affitoxin proteins were evaluated based on daily measurements of tumor volume and body weight. Tumors from mice in the above five groups were separated and weighed after all treatments and observations were finished.

Evaluation of Z_HPV16E7 affitoxin384 immunogenicity

To evaluate the immunogenicity of Z_HPV16E7 affitoxin384 in tumor treatment, we analyzed the levels of Z_HPV16E7 affitoxin384-specific antibody by ELISA using the recombinant Z_HPV16E7 affitoxin384 as an antigen. Briefly, serums were obtained via tail vein bleedings from all groups of mice in the tumor therapy mentioned above at day 0 and day 35, respectively. Then, 200 pmol of purified recombinant Z_{HPV16 E7} affitoxin384 was added to each well of a 96-microtiter plate. After an overnight incubation at 4 °C, the plates were rinsed with PBS solution containing 0.05% Tween-20. The coated wells were blocked with 100 μL blocking buffer (PBST containing 5% nonfat dry milk, w/v) at 37 °C for 1 h then plates were washed 5 times with PBST. Serum samples (at a dilution of 1:100 and 100 μL/well) were added to the wells in triplicate, followed by incubation at 37 °C for 2 h. After the plates were washed 5 times with PBST, the HRP-conjugated goat anti-mouse IgG (H+L) (MultiSciences Biotech Co., Ltd, China) (at w dilution of 1:5000 and 100 μL/well) was added to the corresponding wells and incubated for 1 h at 37 °C. The wells were washed again, followed by the addition of 100 μL/well of 3, 39, 5, 59-tetramethylbenzidine-H₂O₂ solution. The reaction was carried out at room temperature for 20 min and halted with 50 μL of 2 M of H₂SO₄ per well. The absorbance at 450 nm was measured using a Bio-tek ELISA microplate reader.

Statistical analysis

Data are presented as mean ± SD. Statistical analysis of the significance between groups was conducted using Students t-test, and P < 0.05 was considered to be statistically significant. All calculations were performed with the software SPSS16.0.

Results

Generation of Z_{HPV16 E7} affitoxin384

The recombinant plasmids of pET21a (+)/Z_{HPV16 E7} affitoxin384 and pET21a (+)/Z_wt affitoxin were constructed and confirmed by sequencing (Figure 1A). Z_{HPV16 E7} affitoxin384 and Z_wt affitoxin that were expressed in E. coli. BL21 (DE3) were purified and analyzed by SDS-PAGE (Figure 1B-C). The expression of these proteins was confirmed by western blot analysis using anti-His tag mouse monoclonal antibody (Figure 1D), anti-PE38KDEL mouse serum antibody (Figure 1E) and anti-SPA-Z rabbit serum antibody (Figure 1F), respectively. The protein bands at 45 kDa were detected, which were consistent with the expected weights of Z_HPV16E7 affitoxin384 and Z_wt affitoxin. These results indicated that Z_HPV16E7 affitoxin384 or Z_wt affitoxin proteins were expressed in the E. coli. BL21 (DE3) strains and purified successfully.

**Expression and purification of Z_{HPV16 E7} affitoxin 384 protein.** The pET21a (+)/Z_{HPV16 E7} affitoxin384 plasmid was transformed into E. *coli* BL21 (DE3). The protein was expressed and purified by Ni-NTA agarose affinity chromatography. **(A)** Schematic structure of pET21a (+)/Z_{HPV16 E7} affitoxin384 plasmid. **(B)** Comassie blue-stained SDS-PAGE gel of the recombinant proteins. M, protein marker; 1, Empty *E.coli* BL21 (DE3); 2, *E.coli* BL21 (DE3) transformed with pET21a empty vector; 3, *E.coli* BL21 (DE3) transformed with pET21a (+)/Z_{HPV16 E7} affitoxin384 plasmid; 4-5, *E.coli* BL21 (DE3) transformed with pET21a (+)/Z_{HPV16 E7} affitoxin384 plasmid and induced by 1 mM IPTG; 6, *E.coli* BL21 (DE3) transformed with pET21a (+)/Z_wt affitoxin; 7-8, *E.coli* BL21 (DE3) transformed with pET21a (+)/Z_wt affitoxin and induced by 1 mM IPTG. **(C)** Analysis of the purified Z_{HPV16 E7} affitoxin384 and Z_wt affitoxin recombinant proteins by SDS-PAGE. M, protein marker; 1, Z_{HPV16 E7} affitoxin384; 2, Z_wt affitoxin. **(D-F)** Confirmation of the expression of Z_{HPV16 E7} affitoxin384 and Z_wt affitoxin recombinant proteins by western blot using the primary antibodies against His tag, PE38KDEL and SPA-Z, respectively. 1, Empty *E.coli* BL21 (DE3); 2, *E.coli* BL21 (DE3) transformed with pET21a empty vector; 3, *E.coli* BL21 (DE3) transformed with pET21a (+)/Z_{HPV16 E7} affitoxin384 plasmid and induced by 1 mM IPTG; 4, *E.coli* BL21 (DE3) transformed with pET21a (+)/Z_wt affitoxin and induced by 1 mM IPTG.

Z_HPV16E7 affitoxin384 interacted with HPV16 E7 with high binding affinity

SPR assay was performed to evaluate the binding affinity of the Z_HPV16E7 affitoxin384 to HPV16 E7 protein. The data were fit globally using a simple Langmuir binding model (Figure 2 and Table 1). The results showed that the dissociation equilibrium constant (KD) of Z_HPV16E7 affitoxin384 was 2.12×10^-7 M while the counterpart of Z_wt affitoxin was 5.50×10^-2 M, which indicated that the binding affinity of Z_{HPV16 E7} affitoxin384 to HPV16 E7 was significantly higher than that of Z_wt affitoxin.

**Biosensor binding analysis of the purified Z_{HPV16 E7} affitoxin384 protein.** (A) The binding ability of different concentrations of purified Z_{HPV16 E7} affitoxin384 protein to HPV16 E7 protein was tested using SPR-based binding assay. (B) The corresponding concentration of Z_wt affitoxin protein was used as a negative control. All samples were run in triplicate. The smooth curves represent a global analysis of data using a Langmuir binding model.

Table 1.

The kinetic binding constants of Z_{HPV16 E7} affitoxin384 interacting with HPV16 E7 protein.

Binding configuration	k_a (1/Ms)	k_d (1/s)	K_D (M)	n
Z_{HPV16 E7} affitoxin384	1.84×10³	3.91×10^-4	2.12×10^-7	3
Zwt affitoxin	3.00×10^-5	1.65×10^-6	5.50×10^-2	3

Open in a new tab

Z_{HPV16 E7} affitoxin384 interacted with HPV16 E7 with high binding specificity

The binding specificity of Z_{HPV16 E7} affitoxin384 to HPV16 E7 was tested by indirect immunofluorescence assay. SiHa and CaSki cells incubated with Z_{HPV16 E7} affitoxin384 were compared to HeLa and A375 cells as negative controls. The anti-His tag mouse monoclonal antibody, anti-SPA-Z rabbit immune serum antibody and anti-PE38KDEL mouse immune serum antibody were respectively used as the primary antibodies. Cells incubated with Z_{HPV16 E7}384 and Z_wt affitoxin were used as positive and negative controls, respectively. Meanwhile, control cells (no affitoxin incubation), were analyzed using anti-HPV16 E7 rabbit polyclonal antibody as a positive control. As shown in Figure 3A, SiHa and CaSki cells were recognized by anti-HPV16E7 antibody and green fluorescence was observed in these cells whereas HeLa and A375 cells were not recognized by anti-HPV16E7 antibody. When SiHa and CaSki cells were incubated with Z_{HPV16 E7} affitoxin384, all of the three antibodies (anti-His tag mouse monoclonal antibody, anti-SPA-Z rabbit immune serum antibody and anti-PE38KDEL mouse immune serum antibody) recognized the Z_{HPV16 E7} affitoxin384. The fluorescence signals were predominantly located around the nucleus and plasma (Figure 3B-D). Similar results were obtained when SiHa and CaSki cells were incubated with Z_{HPV16 E7}384 (Figure 3E). However, there was no visible signal observed when SiHa and CaSki cells were incubated with Z_wt affitoxin (Figure 3F). Similar negative results were also obtained when HeLa and A375 cells were incubated with Z_{HPV16 E7} affitoxin384 (Figure 3B-D, F).

**Analysis of binding specificity of Z_{HPV16 E7} affitoxin384 to HPV16 E7 by indirect immunofluorescence assay.** SiHa and CaSki cells (HPV16-positive) incubated with Z_{HPV16 E7} affitoxin384 were used as the tested cells. HeLa and A375 cells (HPV16-negative) with the same incubation were used as control cells. **(A)** Cells without incubation with affitoxin were analyzed with anti-HPV16 E7 rabbit serum antibody as positive controls. **(B-D)** Cells incubated with Z_{HPV16 E7} affitoxin384 were analyzed with three different kinds of primary antibodies against His tag, PE38KDEL and SPA-Z, respectively. **(E)** Cells incubated with Z_{HPV16 E7} 384 were analyzed with the primary antibody against His tag as positive control. **(F)** Cells incubated with Z_wt affitoxin were analyzed with the primary antibody against SPA-Z as negative control. All corresponding secondary antibodies were labelled with FITC (green). The nuclei of cells were stained with PI (red). Fluorescence signals were observed using a confocal fluorescence microscope. Scale bar = 10 μm.

To further confirm the binding specificity of Z_{HPV16 E7} affitoxin384 to HPV16 E7, a confocal immunofluorescence co-localization assay was performed. As shown in Figure 4, in SiHa cells, the fluorescence signals of HPV16 E7 and Z_{HPV16 E7} affitoxin384 were co-localized.

**The subcellular co-localization of Z_{HPV16 E7} affitoxin384 with HPV16 E7 in SiHa cells.** SiHa cells that were respectively incubated with Z_wt affitoxin, Z_{HPV16 E7} 384 and Z_{HPV16 E7} Affitoxin 384 were analyzed by indirect immunofluorescence assay. The anti-HPV16E7 rabbit polyclonal antibody and anti-His tag mouse monoclonal antibody were used as primary antibodies. The goat anti-rabbit antibody conjugated with FITC (green) and goat anti-mouse antibody conjugated with alexa fluor 647 (rose red) were used as secondary antibodies. Cell nucleuses were stained with PI (red). The merged images showed the co-localization of Z_{HPV16 E7} affitoxin384 with HPV16 E7 (gray white). Scale bar = 10 μm. White boxes represent selected zoomed area.

Z_{HPV16 E7} affitoxin384 significantly reduced the cell viability of HPV16 positive cells

In order to evaluate the efficacy of Z_{HPV16 E7} affitoxin384 and its potential cytotoxicity, a cell viability assay was performed. Cell viability of SiHa, CaSki, HeLa and A375 cells treated with various concentrations of Z_{HPV16 E7} affitoxin384 was measured using CCK-8 kit. As shown in Figure 5A-B, the cell viability of SiHa and CaSki cells decreased with the increase of concentration of Z_{HPV16 E7} affitoxin384. In contrast, the cells treated with various concentrations of Z_wt affitoxin remained fully viable. The highest concentration at 2 μM was selected for further investigation. The efficacy of Z_{HPV16 E7} affitoxin384 was evaluated in a time course (0, 1, 3, 6, 12, 24, 48 and 72 h). As shown in Figure 5C-D, 2 μM of Z_{HPV16 E7} affitoxin384 significantly reduced the viability of SiHa and CaSki, whereas HeLa and A375 cells treated with the same concentration of Z_{HPV16 E7} affitoxin384 remained fully viable during the indicated time periods. Z_wt affitoxin had no effect on any of the cells tested.

**The efficacy of Z_{HPV16 E7} affitoxin384 in vitro.** SiHa, CaSki, HeLa and A375 cells were treated with different concentrations of Z_{HPV16 E7} affitoxin384 for different time periods. Cell viability was measured using CCK-8 assay. Cells treated with Z_wt affitoxin were used as control. **(A)** SiHa cells were treated with indicated concentrations of Z_{HPV16 E7} affitoxin384 or Z_wt affitoxin for 72 h. **(B)** CaSki cells were treated with indicated concentrations of Z_{HPV16 E7} affitoxin384 or Z_wt affitoxin for 72 h. Compared to the control group, cell viability decreased with the increase of concentration of Z_{HPV16 E7} affitoxin384. **(C)** SiHa, CaSki, HeLa and A375 cells were treated with 2 μM of Z_{HPV16 E7} affitoxin384 for indicated time periods. **(D)** SiHa, CaSki, HeLa and A375 cells were treated with 2 μM of Z_{HPV16 E7} affitoxin384 or Z_wt affitoxin for 72 h. Z_{HPV16 E7} affitoxin384 significantly reduced the viability of SiHa and CaSki cells during the indicated time periods, whereas HeLa and A375 cells treated with the same concentration of Z_{HPV16 E7} affitoxin384 remained fully viable during the indicated time periods. Z_wt affitoxin had no effect on any kinds of cells. **(E)** SiHa cells were treated with indicated concentrations of Z_{HPV16 E7} affitoxin384 or Z_wt affitoxin for 72 h. **(F)** CaSki cells were treated with indicated concentrations of Z_{HPV16 E7} affitoxin384 or Z_wt affitoxin for 72 h. The IC50 values were calculated using GraphPad Prism software. Data are given as mean ± SD (n=3). ^**P <0.01 versus the control group. The IC₅₀ values of Z_{HPV16 E7} affitoxin384 were respectively 3.7×10^-5 and 1.3 ×10^-4 times lower than that of Z_wt affitoxin.

When SiHa and CaSki cells were treated with indicated concentrations of Z_{HPV16 E7} affitoxin384 for 72 h, IC₅₀ values of Z_{HPV16 E7} affitoxin384 were 0.28 μM and 0.24 μM, respectively (data not shown).

Z_{HPV16 E7} affitoxin384 specifically targeted HPV16 positive tumors in tumor-bearing nude mice

NIR optical imaging was performed to determine the in vivo distribution and tumor-targeting ability of Z_{HPV16 E7} affitoxin384. As shown in Figure S1, Z_{HPV16 E7} affitoxin384 was distributed throughout the body within 30 min after injection, excreted by the kidneys, and mainly cleared from the body within 48 h. At 72 hpi, the fluorescent probes had been thoroughly cleared from the body. In order to evaluate the tumor-targeting ability of Z_{HPV16 E7} affitoxin384, nude mice bearing tumor xenografts of SiHa, CaSki, HeLa or A375 cells were used. Fluorescence images were obtained at several time points ranging from 0.5 h to 24 h after injection of Z_HPV16E7384, Z_{HPV16 E7} affitoxin384 or Z_wt affitoxin. The tumor/muscle ratio at 8 hpi was analyzed. As shown in Figure 6A, C, at 2 hpi, xenografts of SiHa and CaSki cells were identified by the Z_HPV16E7384 and Z_{HPV16 E7} affitoxin384 probes, and the intense signal at tumor sites was maintained up to 24 hpi. Tumors in mice injected with Z_HPV16E7384 and Z_{HPV16 E7} affitoxin384 were observed to have significantly higher fluorescence intensity than those injected with Z_wt affitoxin (Figure 6A-D). In contrast, similar tumor-specific fluorescence signals were not detected in nude mice bearing tumor xenografts of HeLa and A375 cells when injected with Z_HPV16E7384 and Z_{HPV16 E7} affitoxin384 (Figure 6E-H).

**The tumor-targeting ability of Z_{HPV16 E7} affitoxin384.** The xenograft-bearing mice were generated with cell lines of **(A)** SiHa, **(C)** CaSki, **(E)** HeLa, and **(G)** A375, respectively. NIR imaging was performed at different time points post injection with DyLight-755-labeled Z_{HPV16 E7} affitoxin384. DyLight-755-labeled Z_{HPV16 E7} 384 and Z_wt affitoxin were used as positive and negative controls, respectively. The tumor/muscle ratios were calculated at 8 h post-injection of indicated agents in xenograft-bearing mice generated with cell lines of **(B)** SiHa, **(D)** CaSki, **(F)** HeLa, and **(H)** A375, respectively. Data are given as mean ± SD (n=5). ^**P <0.01 versus the control group.

After imaging for 48 h, the mice were sacrificed and postmortem fluorescence analysis of dissected organs was performed using the NIR imaging system. According to the results, all animals showed similar Z_{HPV16 E7} affitoxin384 accumulation patterns (data not shown).

Acute toxity and pharmacokinetics of Z_{HPV16 E7} affitoxin384

The toxicity of Z_{HPV16 E7} affitoxin384 was assessed in BALB/c and ICR mice by intravenous injection into the tail vein at the indicated concentrations. As listed in Table S1, a 100% mortality rate was recorded for mice injected with 500 nmol/kg of the protein. Four of 5 mice survived with the treatment of 200 nmol/kg. All death cases were reported within 72 hpi. No mortality was observed in groups treated with 100, 50, 20, 10 or 5 nmol/kg of the protein. The calculated LD50 value was 346.148±83.07 nmol/kg. As listed in Table S2, mice injected with 200 nmol/kg of Z_{HPV16 E7} affitoxin384 showed significantly higher platelet counts compared with control mice at DPI 7 and 14. In addition, all mice injected with any doses of Z_{HPV16 E7} affitoxin384 showed significantly larger mean corpuscular volume compared with control mice at DPI 3. No significant difference was shown in other blood test lists between mice injected with Z_{HPV16 E7} affitoxin384 and control mice. As listed in Table S3, at DPI 1, mice injected with any doses of Z_{HPV16 E7} affitoxin384 showed a significant increase of concentration of aspartate aminotransferase compared with control mice. Then, at DPI 3, the concentration of aspartate aminotransferase returned to a normal level. Additionally, at DPI 3 and 7, mice injected with any doses of Z_{HPV16 E7} affitoxin384 showed a significantly lower concentration of urea nitrogen compared with control mice. No significant difference was shown in other liver and kidney panel test lists between mice injected with Z_{HPV16 E7} affitoxin384 and control mice. Together, these results indicated that injection of Z_{HPV16 E7} affitoxin384 induced a slight damage to mouse liver and kidney initially.

The standard pharmacokinetic curves were made by recombinant HPV16E7 protein-based ELISA (Figure S2). The concentrations of Z_{HPV16 E7} affitoxin384 in serum at different time points post injection are shown in Figure S3.

Pharmacokinetics data obtained by protein-based ELISA indicated that the half-life of Z_{HPV16 E7} affitoxin384 in the bloodstream was 8.95±0.389 min (Figure S3). The initial concentration of Z_{HPV16 E7} affitoxin384 in the plasma was 2.5±2.47 nM at 1 min post injection, which corresponded to the injected dose.

Z_{HPV16 E7} affitoxin384 had significant in vivo antitumor efficacy

Two methods were used to evaluate the therapeutic efficacy of Z_{HPV16 E7} affitoxin384 using SiHa tumor-bearing mice. In the first method, SiHa tumor-bearing mice were prepared in advance. When the tumor size reached 0.1-0.2 cm in diameter, Z_{HPV16 E7} affitoxin384 or other control agents were injected. As shown in Figure 7A, from day 0 to day 15, the tumor sizes from groups injected Z_{HPV16 E7} affitoxin384 and Z_{HPV16 E7}384 decreased gradually whereas those from the other groups increased gradually. After day 15, tumor sizes from all groups began to rise until day 60. However, the tumors from groups of Z_{HPV16 E7} affitoxin384 and Z_{HPV16 E7}384 grew much more slowly than those from other groups. As shown in Figure 7B-C, the tumors from the group of Z_{HPV16 E7} affitoxin384 showed the smallest volume and the lightest weight and there was a significant difference between the tumor weight of Z_{HPV16 E7} affitoxin384 group and those of other groups.

*In vivo* antitumor efficacy of Z_{HPV16 E7} affitoxin384. Therapeutic efficacy of Z_{HPV16 E7} affitoxin384 was studied using SiHa tumor-bearing mice by two methods. **(A)** SiHa tumor-bearing mice were prepared in advance, followed by injection of Z_{HPV16 E7} affitoxin384, Z_wt affitoxin, Z_{HPV16 E7} 384, PE38KDEL, or PBS every three days for 6 times via tail vein. The therapeutic efficacies of affitoxin proteins were evaluated based on daily measurements of tumor volume and body weight. **(B)** Tumors from mice in (A) were separated. **(C)** All tumors from (B) were weighed and compared. **(D)** When SiHa tumor-bearing mice were prepared, cells and Z_{HPV16 E7} affitoxin384, Z_wt affitoxin, Z_{HPV16 E7} 384, PE38KDEL, or PBS were injected at the same time. The therapeutic efficacies of affitoxin proteins were evaluated based on daily measurements of tumor volume and body weight. **(E)** Tumors from mice in (D) were isolated. **(F)** All tumors from (E) were weighed and compared. Data are given as mean ± SD (n=5). ^*P <0.05 versus the control group.

In the second method, Z_{HPV16 E7} affitoxin384 and SiHa cells were injected into nude mice at the same time. As shown in Figure 7D, from day 0 to day 15, tumors were observed in mice of all groups except the Z_{HPV16 E7} affitoxin384 group. Moreover, these tumors grew at a higher speed. At day 30, the tumor sizes from all groups except the Z_{HPV16 E7} affitoxin384 group were over 200 mm³. As shown in in Figure 7E-F, the tumors from the group of Z_{HPV16 E7} affitoxin384 also showed the smallest volume and the lightest weight and there was a significant difference between the tumor weight of the Z_{HPV16 E7} affitoxin384 group and those of the other groups except the Z_{HPV16 E7}384 group.

Immunogenicity of Z_{HPV16 E7} affitoxin384

As reported in a previous study, although nude mice lack a thymus, some immunologic capabilities still remain ³¹. To evaluate the immunogenicity of Z_{HPV16 E7} affitoxin384 in tumor treatment, the levels of Z_{HPV16 E7} affitoxin384-specific antibody at day 0 and day 35 were analyzed by ELISA. As shown in Figure S4, compared to day 0, an increase of anti-ZHPV16 E7 affitoxin384 antibody was detected at day 35 after injection of Z_{HPV16 E7} affitoxin384 every three days for 6 times via tail vein. Meanwhile, an increase of anti-Z_wt affitoxin, anti-Z_{HPV16 E7}384 and anti-PE38KDEL antibodies in control groups was also detected.

Discussion

As reported, 99.7% of cervical tumor specimens were detected with HPV infection, about half of which were HPV 16 positive ²^,³²^,³³. High-risk HPV E7 was proven to be involved in malignant transformation of cervical cancer and the maintenance of tumor cells was dependent on the constant expression of E7 protein ³⁴^-³⁸. Furthermore, E7 protein could interact with several proteins including pRB, p107, p130, p300, p600, CBP, and pCAF ³⁹^,⁴⁰, leading to abnormal cell cycle and genetic instability ⁴⁰^,⁴¹.

Although the HPV-associated cancers could be prevented by the developed prophylactic HPV vaccines to a great extent, these prophylactic HPV vaccines have no therapeutic effect on HPV-associated lesions that result from pre-existing HPV infections ⁴². In addition, it would take a long time for preventive vaccines to lower the prevalence of cervical cancer because of the limited application of prophylactic HPV vaccines due to medical infrastructure problems and high costs ⁴³. Therefore, novel and effective treatment strategies for cervical cancer are urgently needed.

Tumor-specific protein-targeted antibodies have been used in cancer treatment. For instance, the clinical use of a humanized HER2-targeted monoclonal antibody, under the brand name of Herceptin, has significantly improved treatment outcome of breast cancer ¹¹^-¹³. Therapeutic antibodies have various action mechanisms such as binding to their antigens, thereby interfering with the activity of antigens and blocking interaction with binding partners of antigens, triggering complement-dependent cytotoxicity through their Fc portion, and leading to antibody dependent, cell-mediated cytotoxicity (ADCC) by recruiting and activating macrophages, natural killer cells, dendritic cells, and neutrophils (reviewed by Patrick, et al. ¹⁴). However, there are some limitations during the use of these antibodies such as their inadequate pharmacokinetics, poor penetration in tumors, and elimination by the immune system ¹⁴^,⁴⁴. Recently, affibody molecules, a novel category of small affinity proteins with 7 kDa of molecular weight, have been developed and successfully applied to detect HER2-positive tumors in vitro and in xenografts ⁴⁵^-⁵⁵. Compared with antibodies, affibody molecules have no Fc regions, thereby lacking half-life extension and effector function modules. Thus, their therapeutic action can be executed either by blocking interactions of ligand with receptor directly or by carrying toxic payloads (reviewed by Fredrik, et al. ⁵⁶). In subsequent studies, HER2-affitoxin was developed by combining a HER2-specific affibody with modified Pseudomonas aeruginosa Exotoxin A, which was proved to be an attractive agent for treatment of HER2-positive tumors ⁵⁷^,⁵⁸. In a previous study, our group has also produced a series of affibody molecules that can specifically bind with HPV 16 E7 protein both in vitro and in vivo ²⁴. Given that affibody molecules provide rapid tumor localization, fast clearance from non-specific compartments, small size, and low immunogenicity ²⁰, affibody molecules specifically binding with HPV 16 E7 can be used as an excellent vehicle to deliver other therapeutic agents. The mechanism of Z_{HPV16 E7} affitoxin384 is different from that of a monoclonal antibody. Thus, Z_{HPV16 E7} affitoxin384 may serve as a novel and effective treatment strategy for cervical cancer.

As a therapeutic agent for cervical cancer, Z_{HPV16 E7} affitoxin384 must bind to its target protein, HPV16E7, with high specificity. As shown in SPR assay results, the binding affinity of Z_{HPV16 E7} affitoxin384 to HPV16 E7 was about 10⁶ times higher than that of Z_wt affitoxin (Figure 2). Furthermore, by indirect immunofluorescence assay, not only could Z_{HPV16 E7} affitoxin384 bind to HPV16E7 positive cell lines, but also HPV16 E7 and Z_{HPV16 E7} affitoxin384 were co-localized (Figure 3 and Figure 4). The localization of Z_{HPV16 E7} affitoxin384 was similar to that of Z_{HPV16 E7}384 ²⁴. In nude mice bearing tumor xenografts, Z_{HPV16 E7} affitoxin384 could only identify xenografts of HPV16E7 positive cells. The plots of the maximal T/M ratios for all groups of tumor-bearing mice indicated that Z_{HPV16 E7} affitoxin384 showed good tumor-targeting ability to SiHa and CaSki tumors but not to HeLa and A375 tumors, whereas Z_wt affitoxin had no tumor-targeting ability to any kinds of tested tumors (Figure 6). All of these results indicate that Z_{HPV16 E7} affitoxin384 can bind with HPV16 E7 specifically both in vitro and in vivo.

Another feature of a therapeutic agent is that it must be quickly cleared from non-specific tissues. As shown in Figure S1 and Figure S3, Z_{HPV16 E7} affitoxin384 was completely cleared from the mouse body at 72 hpi and the circulation half-life of Z_{HPV16 E7} affitoxin384 in the bloodstream was 8.95±0.389 min, which indicates that Z_{HPV16 E7} affitoxin384 in non-specific tissues can be cleared at a fast rate, much faster than the clearance of HER2-affitoxin reported in a previous study ⁵⁸. Our bio-distribution data showed that Z_{HPV16 E7} affitoxin384 was cleared through the kidneys, which was consistent with the way of clearance of HER2-Affitoxin ⁵⁸. However, there were also some differences between our results and the results from Rafal and colleagues ⁵⁸. HER2-Affitoxin partly accumulated in the livers of mice in their study, whereas Z_{HPV16 E7} affitoxin384 was not observed to accumulate in the liver.

The efficacy and potential cytotoxicity of Z_{HPV16 E7} affitoxin384 were firstly evaluated in vitro. As shown in Figure 5, treatment with Z_{HPV16 E7} affitoxin384 significantly reduced the viability of SiHa and CaSki cells, whereas treatment of HeLa and A375 cells with Z_{HPV16 E7} affitoxin384 and treatment of four kinds of cells with Z_wt affitoxin had no effect on cell viability. These results demonstrate that Z_{HPV16 E7} affitoxin384 specifically affects its target cells and has no detectable cytotoxicity to other unrelated cells.

The efficacy and potential toxicity of Z_{HPV16 E7} affitoxin384 was also evaluated in vivo. As shown in Table S2 and Table S3, injection of Z_{HPV16 E7} affitoxin384 caused only minor effects on mouse liver and kidney. As shown in Figure 7, compared to control groups, the tumor growth of mice administered Z_{HPV16 E7} affitoxin384 was significantly inhibited in both methods we used. However, some difference in the results still existed between the two methods. In the first method, when SiHa tumor-bearing mice were prepared in advance, treatment with Z_{HPV16 E7} affitoxin384 resulted in the reduction of tumor size early, but increased later. Mice treated with Z_{HPV16 E7} affitoxin384 did not show significant weight loss and survived more than 2 months without any signs of organ dysfunction. We speculate that Z_{HPV16 E7} affitoxin384 could kill the outer tumor cells whereas the penetrating ability of Z_{HPV16 E7} affitoxin384 is not strong enough to kill the deeper tumor cells. As a result, tumors from the group of Z_{HPV16 E7} affitoxin384 grew significantly slower than those from other groups. In the second method, tumors were observed in mice of all groups except the Z_{HPV16 E7} affitoxin384 group up to day 15. Tumors grew rapidly in all groups except the Z_{HPV16 E7} affitoxin384 group and tumor sizes were over 200 mm³ by day 30. These results indicate that injecting a mixture of Z_{HPV16 E7} affitoxin384 and SiHa cells into nude mice can effectively inhibit tumor growth. The tumor suppression effect of Z_{HPV16 E7} affitoxin384 in the second method was better than that in the first method. The probable cause may be the complete contact of Z_{HPV16 E7} affitoxin384 with SiHa cells in the second method.

According to our results of an immunogenicity study, injection of Z_{HPV16 E7} affitoxin384 multiple times induced humoral immune response (Figure S4), which was consistent with the results of a previous study ⁵⁸. The generation of Z_{HPV16 E7} affitoxin384-specific antibodies may limit the effectiveness of treatment if these antibodies were neutralizing. This may be another explanation for the reduction of tumor size at the early period of treatment and increase later. Therefore, further studies are still needed to develop a less immunogenic version of the Z_{HPV16 E7} affitoxin384.

In conclusion, our data indicates that Z_{HPV16 E7} affitoxin384 could target HPV16E7 protein with high affinity and specificity. This affitoxin is proven to be a potent anti-cervical cancer therapeutic agent that might be effective against HPV16E7-expressing solid tumors in humans without apparent cytotoxicity to normal cells. These promising data will have to be further confirmed by clinical trials.

Acknowledgments

We thank Deanna Gotte from NIH/NCI for her helpful comments and revisions. This work was supported by the grant from the National Natural Science Foundation of China (Grant No. 81172463 and Grant No. 81502242), Zhejiang Provincial Natural Science Foundation of China (Grant No. LY15H190009), Wenzhou Science and Technology Bureau of China (Grant No. Y20140659) and the Scientific Research Foundation of Wenzhou Medical University (Grant No. QTJ14040).

Abbreviations

CCK-8: Cell Counting Kit-8
DPI: day post-injection
FBS: fetal bovine serum
h: hour
hpi: hours post injection
HPV: human papillomavirus
HPVs: human papillomaviruses
IC₅₀: half maximal inhibitory concentration
IPTG: isopropyl-Dthiogalactopyranoside
LD50: lethal dose 50%
M: mol/L
min: minute
NIR: near-infrared
PE38KDEL: modified Pseudomonas Exotoxin A
PI: propidium iodide
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SPA-Z: Z-domain of staphylococcal protein A
SPR: surface plasmon resonance
T/M ratio: tumor/muscle ratio
Z_{HPV16 E7} affitoxin384: protein encoded by pET21a (+)/Z_{HPV16 E7} affitoxin384 vector
Z_wt: SPA-Z molecule
Z_wt affitoxin: protein encoded by pET21a (+)/Z_wt affitoxin vector.

Supplementary Material

Supplementary figures and tables.

Click here for additional data file.^{(579.6KB, pdf)}

References

1.WHO: Media Centre. Human papillomavirus (HPV) and cervical cancer. Fact sheet. Updated June 2016. http://www.who.int/mediacentre/factsheets/fs380/en/
2.Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
3.zur Hausen H. Papillomaviruses-to vaccination and beyond. Biochemistry (Mosc) 2008;73:498–503. doi: 10.1134/s0006297908050027. [DOI] [PubMed] [Google Scholar]
4.Howley PM, Munger K, Romanczuk H, Scheffner M, Huibregtse JM. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp. 1991;22:239–48. [PubMed] [Google Scholar]
5.Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA. 1992;89:3159–63. doi: 10.1073/pnas.89.7.3159. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res. 2009;69:4407–14. doi: 10.1158/0008-5472.CAN-09-0023. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S. et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol. 2005;114:119–29. doi: 10.1016/j.clim.2004.11.005. [DOI] [PubMed] [Google Scholar]
8.Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM. et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178–87. doi: 10.1158/1078-0432.CCR-07-1880. [DOI] [PubMed] [Google Scholar]
9.Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol. 2011;51:103–8. doi: 10.1111/j.1479-828X.2010.01269.x. [DOI] [PubMed] [Google Scholar]
10.Ratanasiripong NT. A review of human papillomavirus (HPV) infection and HPV vaccine-related attitudes and sexual behaviors among college-aged women in the United States. J Am Coll Health. 2012;60:461–70. doi: 10.1080/07448481.2012.684365. [DOI] [PubMed] [Google Scholar]
11.Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–71. doi: 10.1200/JCO.1998.16.8.2659. [DOI] [PubMed] [Google Scholar]
12.Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48. doi: 10.1200/JCO.1999.17.9.2639. [DOI] [PubMed] [Google Scholar]
13.Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92. doi: 10.1056/NEJM200103153441101. [DOI] [PubMed] [Google Scholar]
14.Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–33. doi: 10.1111/j.1476-5381.2009.00190.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Uhlen M, Guss B, Nilsson B, Gatenbeck S, Philipson L, Lindberg M. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem. 1984;259:1695–702. [PubMed] [Google Scholar]
16.Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E. et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987;1:107–13. doi: 10.1093/protein/1.2.107. [DOI] [PubMed] [Google Scholar]
17.Nord K, Nilsson J, Nilsson B, Uhlen M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995;8:601–8. doi: 10.1093/protein/8.6.601. [DOI] [PubMed] [Google Scholar]
18.Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772–7. doi: 10.1038/nbt0897-772. [DOI] [PubMed] [Google Scholar]
19.Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008;275:2668–76. doi: 10.1111/j.1742-4658.2008.06438.x. [DOI] [PubMed] [Google Scholar]
20.Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670–80. doi: 10.1016/j.febslet.2010.04.014. [DOI] [PubMed] [Google Scholar]
21.Eklund M, Axelsson L, Uhlen M, Nygren PA. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Proteins. 2002;48:454–62. doi: 10.1002/prot.10169. [DOI] [PubMed] [Google Scholar]
22.Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007;7:555–68. doi: 10.1517/14712598.7.4.555. [DOI] [PubMed] [Google Scholar]
23.Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS. et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011;32:2141–8. doi: 10.1016/j.biomaterials.2010.11.053. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Xue X, Wang B, Du W, Zhang C, Song Y, Cai Y. et al. Generation of affibody molecules specific for HPV16 E7 recognition. Oncotarget. 2016;7:73995–4005. doi: 10.18632/oncotarget.12174. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J. 1995;307( Pt 1):29–37. doi: 10.1042/bj3070029. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Lin X, Hou B, Xiong Y, Ye L, Du W, Chen S. et al. Prokaryotic expression of the Z domain of Staphylococcus protein A and preparation of its poly clonal antibody. Jouranl of Wenzhou Medical University. 2015;45:1–5. [Google Scholar]
27.Cen D, Song Y, Zhang C, Mao S, Ye X, Chen J. et al. Prokaryotic expression of recombinant PE38KDEL protein and preparation of its polyclonal antibody. Jouranl of Wenzhou Medical University. 2017;47:1–6. [Google Scholar]
28.Iglewski BH, Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci U S A. 1975;72:2284–8. doi: 10.1073/pnas.72.6.2284. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem. 1989;264:14256–61. [PubMed] [Google Scholar]
30.Liu C, Lin J, Li L, Zhang Y, Chen W, Cao Z. et al. HPV16 early gene E5 specifically reduces miRNA-196a in cervical cancer cells. Sci Rep. 2015;5:7653. doi: 10.1038/srep07653. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Wortis HH. Immunological responses of 'nude' mice. Clin Exp Immunol. 1971;8:305–17. [PMC free article] [PubMed] [Google Scholar]
32.Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80:3812–5. doi: 10.1073/pnas.80.12.3812. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Steele C, Shillitoe EJ. Viruses and oral cancer. Crit Rev Oral Biol Med. 1991;2:153–75. doi: 10.1177/10454411910020020201. [DOI] [PubMed] [Google Scholar]
34.Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 2000;121:216–25. doi: 10.1046/j.1365-2249.2000.01293.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol. 2001;75:4467–72. doi: 10.1128/JVI.75.9.4467-4472.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A. et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8:3676–85. [PubMed] [Google Scholar]
37.Nishimura A, Nakahara T, Ueno T, Sasaki K, Yoshida S, Kyo S. et al. Requirement of E7 oncoprotein for viability of HeLa cells. Microbes Infect. 2006;8:984–93. doi: 10.1016/j.micinf.2005.10.015. [DOI] [PubMed] [Google Scholar]
38.Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology. 2008;375:611–23. doi: 10.1016/j.virol.2008.02.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445:138–68. doi: 10.1016/j.virol.2013.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
40.de Freitas AC, Coimbra EC, Leitao Mda C. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta. 2014;1845:91–103. doi: 10.1016/j.bbcan.2013.12.004. [DOI] [PubMed] [Google Scholar]
41.Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M. et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451–60. doi: 10.1128/JVI.78.21.11451-11460.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167–73. doi: 10.1172/JCI28607. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries—key challenges and issues. N Engl J Med. 2007;356:1908–10. doi: 10.1056/NEJMp078053. [DOI] [PubMed] [Google Scholar]
44.Bourgeois M, Bailly C, Frindel M, Guerard F, Cherel M, Faivre-Chauvet A. et al. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opin Biol Ther. 2017;17:813–9. doi: 10.1080/14712598.2017.1322577. [DOI] [PubMed] [Google Scholar]
45.Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, Gedda L. et al. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846–53. [PubMed] [Google Scholar]
46.Lundberg E, Hoiden-Guthenberg I, Larsson B, Uhlen M, Graslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods. 2007;319:53–63. doi: 10.1016/j.jim.2006.10.013. [DOI] [PubMed] [Google Scholar]
47.Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M. et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178–86. doi: 10.1158/0008-5472.CAN-06-2887. [DOI] [PubMed] [Google Scholar]
48.Tran T, Engfeldt T, Orlova A, Sandstrom M, Feldwisch J, Abrahmsen L. et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem. 2007;18:1956–64. doi: 10.1021/bc7002617. [DOI] [PubMed] [Google Scholar]
49.Ekblad T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L. et al. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245–55. doi: 10.1007/s00259-008-0845-7. [DOI] [PubMed] [Google Scholar]
50.Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35:1008–18. doi: 10.1007/s00259-007-0658-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G. et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res. 2008;14:3840–9. doi: 10.1158/1078-0432.CCR-07-4076. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, Nilsson FY. et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep. 2008;19:853–7. doi: 10.3892/or.19.4.853. [DOI] [PubMed] [Google Scholar]
53.Friedman M, Lindstrom S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H. et al. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem. 2009;54:121–31. doi: 10.1042/BA20090096. [DOI] [PubMed] [Google Scholar]
54.Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, Hodik M. et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med. 2009;50:274–83. doi: 10.2967/jnumed.108.055525. [DOI] [PubMed] [Google Scholar]
55.Nordberg E, Ekerljung L, Sahlberg SH, Carlsson J, Lennartsson J, Glimelius B. Effects of an EGFR-binding affibody molecule on intracellular signaling pathways. Int J Oncol. 2010;36:967–72. doi: 10.3892/ijo_00000576. [DOI] [PubMed] [Google Scholar]
56.Frejd FY, Kim KT. Affibody molecules as engineered protein drugs. Exp Mol Med. 2017;49:e306. doi: 10.1038/emm.2017.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N. et al. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother. 2009;32:817–25. doi: 10.1097/CJI.0b013e3181ad4d5d. [DOI] [PMC free article] [PubMed] [Google Scholar]
58.Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A. et al. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res. 2011;17:5071–81. doi: 10.1158/1078-0432.CCR-10-2887. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary figures and tables.

Click here for additional data file.^{(579.6KB, pdf)}

[B1] 1.WHO: Media Centre. Human papillomavirus (HPV) and cervical cancer. Fact sheet. Updated June 2016. http://www.who.int/mediacentre/factsheets/fs380/en/

[B2] 2.Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]

[B3] 3.zur Hausen H. Papillomaviruses-to vaccination and beyond. Biochemistry (Mosc) 2008;73:498–503. doi: 10.1134/s0006297908050027. [DOI] [PubMed] [Google Scholar]

[B4] 4.Howley PM, Munger K, Romanczuk H, Scheffner M, Huibregtse JM. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp. 1991;22:239–48. [PubMed] [Google Scholar]

[B5] 5.Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA. 1992;89:3159–63. doi: 10.1073/pnas.89.7.3159. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B6] 6.Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res. 2009;69:4407–14. doi: 10.1158/0008-5472.CAN-09-0023. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B7] 7.Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S. et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol. 2005;114:119–29. doi: 10.1016/j.clim.2004.11.005. [DOI] [PubMed] [Google Scholar]

[B8] 8.Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Berends-van der Meer DM. et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178–87. doi: 10.1158/1078-0432.CCR-07-1880. [DOI] [PubMed] [Google Scholar]

[B9] 9.Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol. 2011;51:103–8. doi: 10.1111/j.1479-828X.2010.01269.x. [DOI] [PubMed] [Google Scholar]

[B10] 10.Ratanasiripong NT. A review of human papillomavirus (HPV) infection and HPV vaccine-related attitudes and sexual behaviors among college-aged women in the United States. J Am Coll Health. 2012;60:461–70. doi: 10.1080/07448481.2012.684365. [DOI] [PubMed] [Google Scholar]

[B11] 11.Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–71. doi: 10.1200/JCO.1998.16.8.2659. [DOI] [PubMed] [Google Scholar]

[B12] 12.Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48. doi: 10.1200/JCO.1999.17.9.2639. [DOI] [PubMed] [Google Scholar]

[B13] 13.Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92. doi: 10.1056/NEJM200103153441101. [DOI] [PubMed] [Google Scholar]

[B14] 14.Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–33. doi: 10.1111/j.1476-5381.2009.00190.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B15] 15.Uhlen M, Guss B, Nilsson B, Gatenbeck S, Philipson L, Lindberg M. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem. 1984;259:1695–702. [PubMed] [Google Scholar]

[B16] 16.Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E. et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987;1:107–13. doi: 10.1093/protein/1.2.107. [DOI] [PubMed] [Google Scholar]

[B17] 17.Nord K, Nilsson J, Nilsson B, Uhlen M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995;8:601–8. doi: 10.1093/protein/8.6.601. [DOI] [PubMed] [Google Scholar]

[B18] 18.Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772–7. doi: 10.1038/nbt0897-772. [DOI] [PubMed] [Google Scholar]

[B19] 19.Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008;275:2668–76. doi: 10.1111/j.1742-4658.2008.06438.x. [DOI] [PubMed] [Google Scholar]

[B20] 20.Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670–80. doi: 10.1016/j.febslet.2010.04.014. [DOI] [PubMed] [Google Scholar]

[B21] 21.Eklund M, Axelsson L, Uhlen M, Nygren PA. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Proteins. 2002;48:454–62. doi: 10.1002/prot.10169. [DOI] [PubMed] [Google Scholar]

[B22] 22.Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007;7:555–68. doi: 10.1517/14712598.7.4.555. [DOI] [PubMed] [Google Scholar]

[B23] 23.Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS. et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011;32:2141–8. doi: 10.1016/j.biomaterials.2010.11.053. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B24] 24.Xue X, Wang B, Du W, Zhang C, Song Y, Cai Y. et al. Generation of affibody molecules specific for HPV16 E7 recognition. Oncotarget. 2016;7:73995–4005. doi: 10.18632/oncotarget.12174. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B25] 25.Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J. 1995;307( Pt 1):29–37. doi: 10.1042/bj3070029. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B26] 26.Lin X, Hou B, Xiong Y, Ye L, Du W, Chen S. et al. Prokaryotic expression of the Z domain of Staphylococcus protein A and preparation of its poly clonal antibody. Jouranl of Wenzhou Medical University. 2015;45:1–5. [Google Scholar]

[B27] 27.Cen D, Song Y, Zhang C, Mao S, Ye X, Chen J. et al. Prokaryotic expression of recombinant PE38KDEL protein and preparation of its polyclonal antibody. Jouranl of Wenzhou Medical University. 2017;47:1–6. [Google Scholar]

[B28] 28.Iglewski BH, Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci U S A. 1975;72:2284–8. doi: 10.1073/pnas.72.6.2284. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B29] 29.Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem. 1989;264:14256–61. [PubMed] [Google Scholar]

[B30] 30.Liu C, Lin J, Li L, Zhang Y, Chen W, Cao Z. et al. HPV16 early gene E5 specifically reduces miRNA-196a in cervical cancer cells. Sci Rep. 2015;5:7653. doi: 10.1038/srep07653. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B31] 31.Wortis HH. Immunological responses of 'nude' mice. Clin Exp Immunol. 1971;8:305–17. [PMC free article] [PubMed] [Google Scholar]

[B32] 32.Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80:3812–5. doi: 10.1073/pnas.80.12.3812. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B33] 33.Steele C, Shillitoe EJ. Viruses and oral cancer. Crit Rev Oral Biol Med. 1991;2:153–75. doi: 10.1177/10454411910020020201. [DOI] [PubMed] [Google Scholar]

[B34] 34.Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 2000;121:216–25. doi: 10.1046/j.1365-2249.2000.01293.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B35] 35.Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol. 2001;75:4467–72. doi: 10.1128/JVI.75.9.4467-4472.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B36] 36.Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A. et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8:3676–85. [PubMed] [Google Scholar]

[B37] 37.Nishimura A, Nakahara T, Ueno T, Sasaki K, Yoshida S, Kyo S. et al. Requirement of E7 oncoprotein for viability of HeLa cells. Microbes Infect. 2006;8:984–93. doi: 10.1016/j.micinf.2005.10.015. [DOI] [PubMed] [Google Scholar]

[B38] 38.Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology. 2008;375:611–23. doi: 10.1016/j.virol.2008.02.025. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B39] 39.Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445:138–68. doi: 10.1016/j.virol.2013.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B40] 40.de Freitas AC, Coimbra EC, Leitao Mda C. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta. 2014;1845:91–103. doi: 10.1016/j.bbcan.2013.12.004. [DOI] [PubMed] [Google Scholar]

[B41] 41.Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M. et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451–60. doi: 10.1128/JVI.78.21.11451-11460.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B42] 42.Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167–73. doi: 10.1172/JCI28607. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B43] 43.Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries—key challenges and issues. N Engl J Med. 2007;356:1908–10. doi: 10.1056/NEJMp078053. [DOI] [PubMed] [Google Scholar]

[B44] 44.Bourgeois M, Bailly C, Frindel M, Guerard F, Cherel M, Faivre-Chauvet A. et al. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opin Biol Ther. 2017;17:813–9. doi: 10.1080/14712598.2017.1322577. [DOI] [PubMed] [Google Scholar]

[B45] 45.Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, Gedda L. et al. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846–53. [PubMed] [Google Scholar]

[B46] 46.Lundberg E, Hoiden-Guthenberg I, Larsson B, Uhlen M, Graslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods. 2007;319:53–63. doi: 10.1016/j.jim.2006.10.013. [DOI] [PubMed] [Google Scholar]

[B47] 47.Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M. et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178–86. doi: 10.1158/0008-5472.CAN-06-2887. [DOI] [PubMed] [Google Scholar]

[B48] 48.Tran T, Engfeldt T, Orlova A, Sandstrom M, Feldwisch J, Abrahmsen L. et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem. 2007;18:1956–64. doi: 10.1021/bc7002617. [DOI] [PubMed] [Google Scholar]

[B49] 49.Ekblad T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L. et al. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245–55. doi: 10.1007/s00259-008-0845-7. [DOI] [PubMed] [Google Scholar]

[B50] 50.Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35:1008–18. doi: 10.1007/s00259-007-0658-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B51] 51.Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G. et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res. 2008;14:3840–9. doi: 10.1158/1078-0432.CCR-07-4076. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B52] 52.Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, Nilsson FY. et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep. 2008;19:853–7. doi: 10.3892/or.19.4.853. [DOI] [PubMed] [Google Scholar]

[B53] 53.Friedman M, Lindstrom S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H. et al. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem. 2009;54:121–31. doi: 10.1042/BA20090096. [DOI] [PubMed] [Google Scholar]

[B54] 54.Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, Hodik M. et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med. 2009;50:274–83. doi: 10.2967/jnumed.108.055525. [DOI] [PubMed] [Google Scholar]

[B55] 55.Nordberg E, Ekerljung L, Sahlberg SH, Carlsson J, Lennartsson J, Glimelius B. Effects of an EGFR-binding affibody molecule on intracellular signaling pathways. Int J Oncol. 2010;36:967–72. doi: 10.3892/ijo_00000576. [DOI] [PubMed] [Google Scholar]

[B56] 56.Frejd FY, Kim KT. Affibody molecules as engineered protein drugs. Exp Mol Med. 2017;49:e306. doi: 10.1038/emm.2017.35. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B57] 57.Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N. et al. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother. 2009;32:817–25. doi: 10.1097/CJI.0b013e3181ad4d5d. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B58] 58.Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A. et al. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res. 2011;17:5071–81. doi: 10.1158/1078-0432.CCR-10-2887. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer

Pengfei Jiang

Lude Wang

Bailong Hou

Jinshun Zhu

Meng Zhou

Jie Jiang

Ledan Wang

Shao Chen

Shanli Zhu

Jun Chen

Lifang Zhang

Abstract

Introduction

Methods

Animals, cells and vectors

Reagents

Expression and purification of ZHPV16E7 affitoxin384

Western blot analysis

Surface plasmon resonance assay

Indirect immunofluorescence assay

In vitro efficacy of ZHPV16 E7 affitoxin384

Tumor targeting ability of ZHPV16 E7 affitoxin384 in tumor-bearing nude mice

Evaluation of ZHPV16 E7 affitoxin384 acute toxicity

Pharmacokinetics of ZHPV16 E7 affitoxin384

In vivo antitumor efficacy of ZHPV16 E7 affitoxin384

Evaluation of ZHPV16E7 affitoxin384 immunogenicity

Statistical analysis

Results

Generation of ZHPV16 E7 affitoxin384

Figure 1.

ZHPV16E7 affitoxin384 interacted with HPV16 E7 with high binding affinity

Figure 2.

Table 1.

ZHPV16 E7 affitoxin384 interacted with HPV16 E7 with high binding specificity

Figure 3.

Figure 4.

ZHPV16 E7 affitoxin384 significantly reduced the cell viability of HPV16 positive cells

Figure 5.

ZHPV16 E7 affitoxin384 specifically targeted HPV16 positive tumors in tumor-bearing nude mice

Figure 6.

Acute toxity and pharmacokinetics of ZHPV16 E7 affitoxin384

ZHPV16 E7 affitoxin384 had significant in vivo antitumor efficacy

Figure 7.

Immunogenicity of ZHPV16 E7 affitoxin384

Discussion

Acknowledgments

Abbreviations

Supplementary Material

References

Associated Data

Supplementary Materials

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Expression and purification of Z_HPV16E7 affitoxin384

In vitro efficacy of Z_{HPV16 E7} affitoxin384

Tumor targeting ability of Z_{HPV16 E7} affitoxin384 in tumor-bearing nude mice

Evaluation of Z_{HPV16 E7} affitoxin384 acute toxicity

Pharmacokinetics of Z_{HPV16 E7} affitoxin384

In vivo antitumor efficacy of Z_{HPV16 E7} affitoxin384

Evaluation of Z_HPV16E7 affitoxin384 immunogenicity

Generation of Z_{HPV16 E7} affitoxin384

Z_HPV16E7 affitoxin384 interacted with HPV16 E7 with high binding affinity

Z_{HPV16 E7} affitoxin384 interacted with HPV16 E7 with high binding specificity

Z_{HPV16 E7} affitoxin384 significantly reduced the cell viability of HPV16 positive cells

Z_{HPV16 E7} affitoxin384 specifically targeted HPV16 positive tumors in tumor-bearing nude mice

Acute toxity and pharmacokinetics of Z_{HPV16 E7} affitoxin384

Z_{HPV16 E7} affitoxin384 had significant in vivo antitumor efficacy

Immunogenicity of Z_{HPV16 E7} affitoxin384